Drug information provided by: Merative, Micromedex®
Elexacaftor/tezacaftor/ivacaftor and ivacaftor combination is used to treat cystic fibrosis (CF) in patients who have at least one copy of F508del mutation in their CF transmembrane conductance regulator (CFTR) gene or another mutation that is responsive to this medicine. Your doctor will use a test to check for the mutation before you receive the medicine.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Sept. 01, 2023
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
A generous benefactor has pledged $1 million and challenged us to raise an additional $250,000. Help us reach our goal!